RoActemra((R)) (Tocilizumab) - Rapid and persistent Remission in RA when DMARDs fail

被引：0
作者：
不详
机构：
来源：
JOURNAL FUR MINERALSTOFFWECHSEL | 2009年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：162 / 162
页数：1
相关论文
共 4 条
  • [1] Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
    Genovese, Mark C.
    McKay, James D.
    Nasonov, Evgeny L.
    Mysler, Eduardo F.
    da Silva, Nilzio A.
    Alecock, Emma
    Woodworth, Thasia
    Gomez-Rein, Juan J.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (10): : 2968 - 2980
  • [2] Kremer JM, 2008, ACR ARHP 2009 AM COL
  • [3] Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    Smolen, Josef S.
    Beaulieu, Andre
    Rubbert-Roth, Andrea
    Ramos-Remus, Cesar
    Rovensky, Josef
    Alecock, Emma
    Woodworth, Thasia
    Alten, Rieke
    [J]. LANCET, 2008, 371 (9617) : 987 - 997
  • [4] van Vollenhoven RF, 2009, EULAR 2009 ANN EUR C
1